Austin Person
Colon & Rectal Surgery · Omaha, NENPI 1265840243
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (39.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 90.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $5,065 and has fallen 99.3% since, to $36 in 2025.
Across 41 payments — averaging $152.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Medtronic$279
- AbbVie$90
- Integra Lifesciences Corporation$56
- Boston Scientific$55
- Takeda Pharmaceuticals U.S.A., Inc.$39
- plus $106 from 6 others
What the payments were for
- Travel & lodging$2,37438%
- Food & beverage$1,37522%
- Education$2,50040%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $5,632 |
| Medtronic | 4 | $279 |
| AbbVie | 4 | $90 |
| Integra Lifesciences Corporation | 3 | $56 |
| Boston Scientific | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Johnson & Johnson | 1 | $24 |
| Stryker | 1 | $23 |
| RTI Surgical, Inc | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Coloplast | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,779
- DAVINCI XI$2,500
- INTERSTIM$157
How this compares
Too few colon & rectal surgery providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colestipol Hcl | 35 | $3,229 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 71 | $1,038 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $362 |
| Neomycin Sulfate | 29 | $160 |
| Oxycodone Hcl | 24 | $134 |
| Metronidazole | 30 | $55 |
| Tramadol Hcl | 20 | $49 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Omaha
- Alan ThorsonOmaha$24K
- Hernan HernandezOmaha$9K
- Charles TernentOmaha$7K
- Zachary TorgersenOmaha$3K
- Maniamparampil ShashidharanOmaha$915
- Jennifer LeinickeOmaha$563
- Jennifer BeatyOmaha$390
- Garnet BlatchfordOmaha$315
- Michael JobstLincoln$131K
- Kelly KrierLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.